Product
KSL
1 clinical trial
1 indication
Indication
Pain DisordersClinical trial
2-way Crossover, Single Dose Randomized Bioequivalence Phase I Study of Ketoprofen Lysine Salt as Immediate Release Tablets Formulation (40 mg) vs. Oral Solution (80 mg, Half Sachet) After Oral Administration to Healthy Volunteers.Status: Completed, Estimated PCD: 2014-12-16